drugset / Trial / NCT02302430
Intranasal Oxytocin and Enhancement of Team Cohesion
Phase 1
Completed
486 enrolled
University of California, San Francisco
San Francisco Veterans Affairs Medical Center · collabUnited States Department of Defense · collab
RandomizedParallel-groupTriple-blindOther
Summary
This study attempts to identify the psychological, behavioral, physiological, and hormonal predictors and mechanisms of an individual's ability to develop cohesion in a group working together as a team; and examine if administration of the prosocial neuropeptide oxytocin enhances the development of team cohesion. Through a deeper understanding of the underlying psychobiological predictors and mechanisms of team cohesion, the prospective identification of individuals whose unique characteristics promote or inhibit the development of group cohesion will become possible.
Timeline
- Start
- 2015-10
- Primary completion
- 2018-05
- Completion
- 2019-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxytocin | Peptide | 20 iu | Intranasal |
| Subject | Oxytocin | Peptide | 40 iu | Intranasal |
Indications
No indication recorded.